

Effect of tetramethylpyrazine on exocrine pancreatic and bile secretion

Wen-Chao Zhao, Jin-Xia Zhu, Ning Tang, Yu-Lin Gou, Dewi Kenneth Rowlands, Yiu-Wa Chung, Ying Xing, Hsiao-Chang Chan

Yu-Lin Gou, Dewi Kenneth Rowlands, Yiu-Wa Chung, Hsiao-Chang Chan, Epithelial Cell Biology Research Center, Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong

Wen-Chao Zhao, Jin-Xia Zhu, Ning Tang, Ying Xing, Department of Physiology, Medical School, Zhengzhou University, Zhengzhou 450052, Henan, Province China

Supported by Innovation and Technology Funds of Hong Kong and strategic Program of the Chinese University of Hong Kong

Correspondence to: Professor Hsiao-Chang Chan, Epithelial Cell Biology Research Center, The Department of Physiology, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, SAR, China. hsiaochan@cuhk.edu.hk

Telephone: +852-2609-6839 **Fax:** +852-2603-5022

Received: 2003-05-11 **Accepted:** 2003-08-19

Abstract

AIM: To investigate the effect of tetramethylpyrazine (ligustrazine, TMP) on the secretion of exocrine pancreas (and biliary).

METHODS: In *in vivo* study, we investigated the effect of TMP on the secretion of pancreatic-bile juice (PBJ) in rats. Using human pancreatic duct cell line, CAPAN-1, combined with the short-circuit current (I_{sc}) technique we further studied the effect of TMP on the pancreatic anion secretion.

RESULTS: Administration of TMP (80 mg/kg, ip) significantly increased the secretion of PBJ ($P < 0.05$), but the pH of PBJ and the secretion of pancreatic protein were not significantly affected. Basolateral addition of TMP produced a dose-dependent increase in I_{sc} ($EC_{50} = 1.56$ mmol/L), which contained a fast transient I_{sc} response followed by a slow decay. Apical application of Cl^- channel blockers, DPC (1 mmol/L), decreased the response by about 67.1 % ($P < 0.001$), whereas amiloride (100 μ mol/L), a epithelial sodium channel blockers, had no effect. Removal of extracellular HCO_3^- abolished TMP-induced increase in I_{sc} by about 74.4 % ($P < 0.001$), but the removal of external Cl^- did not. Pretreatment with phosphodiesterase inhibitor, IBMX (0.5 mmol/L), decreased the TMP-induced I_{sc} by 91 % ($P < 0.001$).

CONCLUSION: TMP could stimulate the secretion of PBJ, especially pancreatic ductal HCO_3^- secretion via cAMP or cGMP-dependent pathway. It need further study to investigate the roles of cAMP or cGMP in the effect of TMP on the secretion of exocrine pancreas.

Zhao WC, Zhu JX, Tang N, Gou YL, Rowlands DK, Chung YW, Xing Y, Chan HC. Effect of tetramethylpyrazine on exocrine pancreatic and bile secretion. *World J Gastroenterol* 2003; 9 (11): 2505-2508

<http://www.wjgnet.com/1007-9327/9/2505.asp>

INTRODUCTION

Tetramethylpyrazine (TMP, $C_8H_{12}N_2$, molecular mass 136.20 u,

also known as ligustrazine) is an active alkaloid contained in the rhizome of *Chuanxiong*^[1]. TMP has been widely used for the treatment of patients with cardiovascular and cerebrovascular diseases^[1-5]. Its proposed pharmacological actions include antagonizing calcium mobilization^[6], inhibiting platelet aggregation^[7] and increasing intracellular cAMP level by inhibiting phosphodiesterase activity^[8]. Recently it has been reported that TMP has antioxidant effect, reducing free radical generation^[9,10] and decreasing nitric oxide production^[11,12]. However, the effect of TMP on the pancreatic exocrine secretion are unknown. Since TMP is known to activate cAMP, it may act similarly to secretin, a physiological regulator of pancreatic secretion by elevating intracellular cAMP to act on pancreatic epithelial CFTR, which is a cAMP/cGMP-regulated Cl^- channel^[13,14] and involved in pancreatic HCO_3^- secretion. In the present study, we investigated the effect of TMP on the secretion of pancreatic-bile juice (PBJ), which includes both pancreatic protein and HCO_3^- . We also undertook the present study using the short-circuit current (I_{sc}) technique to investigate TMP effect on HCO_3^- secretion by human pancreatic duct cell line, CAPAN-1, which retains most of the properties of pancreatic duct cells^[15,16].

MATERIALS AND METHODS

Materials

Hydrochloride tetramethylpyrazine was purchased from the First Chengdu pharmaceutical Factory (Chengdu, China). RPMI 1640 medium and fetal bovine serum, trypsin-EDTA were supplied by Gibco Laboratories (New York). Hanks' balanced salt solution (HBSS), diphenylamine-2, 2' -dicarboxylic acid (DPC), glucose, calcium gluconate, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), sodium bicarbonate, DMEG, penicillin-streptomycin (P/S) and Bradford reagent were supplied by Sigma Chemical (St.Louis, MO). Calcium chloride, magnesium sulfate, potassium chloride, sodium chloride, were obtained from Merck (Darmstadt, Germany). Potassium gluconate and sodium gluconate were from BDH Chemicals (Poole, England). Tris was from Amersham Biosciences (Stockholm, Sweden).

Methods

Animal preparation Animal experimentation was conducted according to institutional guidelines. Adult male Sprague-Dawley rats, weighing 220-280 g, were housed under controlled temperature (23 °C) and fasted for 12 h with free access to water before surgery. Midline abdominal incisions were made under xylazine and ketamine anesthesia (13 and 87 mg/kg body weight, respectively, im), followed by insertion of a polyethylene tube into the proximal duodenum for diversion of PBJ to the duodenum. A pancreatic duct cannula was made by inserting a polyethylene tube at the junction between the pancreatic duct and the duodenal wall for collection of PBJ^[17-19].

Collection and measurement of exocrine pancreatic-bile secretions The animals were divided into two groups randomly: TMP group (TMP 80 mg/kg, ip, pH 2.3) and control

group (9 g/L NaCl solution, ip. pH 2.3). After a 30-minute stabilization period, pancreatic-bile secretions were collected every 15 minutes for 90 minutes. The volume was measured by a 1mL syringe and the pH value of PBJ was determined by a pH analyzer. 10 μ L of PBJ was taken and diluted for pancreatic protein determination using spectra MAX 250 and Bradford reagent. The remaining undiluted PBJ was pumped into the duodenum via the duodenal cannula during the next collection period. Administrations were given after 2-time collections (30 minutes) and the second 15-minute-secretion was the basal PBJ secretion.

Cell culture Experiments were performed on the human pancreatic duct cell line, CAPAN-1 at a passage of 50-58. Cells were grown in RPMI 1640 medium with 200 mL/L fetal bovine serum and 10 g/L penicillin-streptomycin (P/S) as described previously^[20,21]. Briefly, a volume of 0.2 mL of the cell suspension (1.5×10^9 /L) was plated onto each permeable support, which was made of a millipore filter and a silicon ring with a confined area of 0.45 cm², floating on culture medium and incubated at 37 °C with 50 mL/L CO₂ and 950 mL/L O₂ for 7-8 days. The cells were used for I_{SC} once the monolayers reached confluence.

Short-circuit current measurement The basic principles of the short-circuit current experiments performed in the present study were the same as previously described^[20,21]. Monolayers grown on permeable supports were clamped vertically between two halves of the Ussing chamber and bathed in Krebs-Henseleit (K-H) solutions with following compositions (mmol/L): NaCl, 117; KCl, 4.7; MgSO₄, 1.2; KH₂PO₄, 1.2; NaHCO₃, 24.8; CaCl₂, 2.56; Glucose, 11.1; with an osmolarity of 285 gassed with 950 mL/L O₂ and 50 mL/L CO₂. In some experiments, gluconate was used to replace Cl⁻. For HCO₃⁻-free solution, HEPES and Tris were used and the solution was gassed in air. All the electrodes were connected to the voltage-current clamp amplifier. The signal output from the amplifier was the I_{SC} measured and recorded online by chart recorders. A 0.1 mV voltage pulse was applied intermittently across the epithelium and the transepithelial resistance was calculated from the corresponding current changes.

Statistical analysis

The data were collected and analyzed by SPSS statistical package 10.0. The results were expressed as $\bar{x} \pm S_{\bar{x}}$. Comparisons between groups of data were carried out using Student's paired or unpaired *t*-test. Comparisons in one group of data were carried out using One-way ANOVA. A *P*-value less than 0.05 was considered to be statistically significant. EC₅₀ values were determined by non-linear regression by GraphPad Prism software.

RESULTS

Effect of TMP on secretion of PBJ

Table 1 shows the volume of pancreatic-bile juice (PBJ) collected at different time points before and after intraperitoneal administration of TMP or 9 mL/L NaCl (control). Compared with the basal secretion, the PBJ secretion in TMP treated rats was increased by 7.0 % (*P*<0.05), 22.3 % (*P*<0.001), 14.3 % (*P*<0.01), 18.2 % (*P*<0.01) and 14.2 % (*P*<0.01) at 15, 30, 45, 60 and 75 minutes, respectively (*n*=13) (Figure 1). However, the same treatment with of 9 mL/L NaCl solution did not produce significant effect (*n*=12) (Figure 1). Protein content in PBJ and pH of PBJ were shown to have no differences between TMP-treated and control groups (data not shown).

Effect of TMP on CAPAN-1 cell line

The CAPAN-1 monolayer clamped in Ussing chambers

bathing with normal K-HS (Cl⁻/HCO₃⁻-containing) exhibited a potential difference of 0.52 ± 0.04 mV, basal I_{SC} of 5.70 ± 0.53 μ A/cm² and transmembrane resistance of 93.6 ± 4.5 Ω cm² (*n*=77). In Cl⁻-free (*n*=9) and HCO₃⁻-free (*n*=9) K-H solution, the transepithelial potential difference was 0.62 ± 0.15 mV and 0.86 ± 0.28 mV and the basal I_{SC} was 1.90 ± 0.50 μ A/cm² and 3.98 ± 1.32 μ A/cm², respectively, and the resistance of the monolayers were 208.6 ± 33.6 Ω cm² and 161.8 ± 25.6 Ω cm².

Table 1 Volume of secretion of pancreatic bile juice ($\bar{x} \pm S_{\bar{x}}$, μ L)

	Groups	TMP <i>n</i> =13	Control <i>n</i> =12
After administration	Basal	372.3 \pm 22.2	342.5 \pm 15.8
	15 min	398.5 \pm 23.3	326.7 \pm 1.74
	30 min	455.4 \pm 18.8	344.2 \pm 14.5
	45 min	425.4 \pm 19.8	331.7 \pm 17.5
	60 min	440.0 \pm 25.8	357.5 \pm 18.8
	75 min	425.0 \pm 25.2	342.5 \pm 18.2




Figure 1 Effect of TMP on Volume of pancreatic-bile juice secretion. The volume of pancreatic-bile juice secretion collected before (basal) and 15, 30, 45, 60 and 75 minutes after intraperitoneal administration of TMP (80 mg/kg) and 9 mL/L NaCl in rats. The results were expressed as $\bar{x} \pm S_{\bar{x}}$. ^a*P*<0.05, ^b*P*<0.01, ^c*P*<0.001, as compared to basal values.




Figure 2 Concentration-response curve for TMP-induced I_{SC} in CAPAN-1 cells. Different concentrations of TMP were added to basolateral side. Each data point was obtained from at least 4 individual experiments. Arrow shows EC₅₀.

Basolateral addition of TMP (0.05, 0.15, 0.5, 1.5, 5 and 10 mmol/L) produced a dose-dependent increase in I_{SC}. EC₅₀ was about 1.56 mmol/L (Figure 2). TMP (5 mmol/L)-induced I_{SC} increase was biphasic: a fast transient peak followed by a slow decay. The total transported charges for 15 minutes (the area under the curve of the TMP-induced I_{SC} response) were about 1.06 ± 0.99 mC/cm² (*n*=27, Figure 3.A and C). TMP-induced current increase was inhibited by 67.1 % after apical pretreatment of 1 mmol/L DPC, a non-specific Cl⁻ channel blockers (*n*=8, *P*<0.001) (Figure 3.B and C). However apical application of epithelial sodium channel blockers, amiloride

(100 $\mu\text{mol/L}$) did not affect the TMP-produced response ($n=3$, Figure 3.C). After the removal of external HCO_3^- , TMP-induced I_{SC} was blocked by 74.4 % ($n=9$, $P<0.001$) (Figure 3.D), but the removal of external Cl^- did not reduce but increase the TMP-induced I_{SC} ($n=8$, $P<0.05$) (Figure 3.D). Pretreatment of phosphodiesterase inhibitor, IBMX (0.5 mmol/L) for 15 minutes decreased the TMP-induced I_{SC} by 91 % ($n=4$, $P<0.001$) (Figure 4.A and B).




Figure 3 TMP-induced HCO_3^- secretion in CAPAN-1 cells. Comparison of TMP (5 mmol/L)-induced I_{SC} (mC/cm^2) obtained in control (A, C), pretreatment with DPC (1 mmol/L) (B, C), Amiloride 100 $\mu\text{mol/L}$ (C), HCO_3^- -free solution (D), Cl^- -free solution (D). Values are $\bar{x} \pm s$, $^a P<0.05$, $^c P<0.001$.

DISCUSSION

While TMP has been widely used clinically for treating cardiovascular disorders and cerebrovascular diseases^[1-5], little is known about its effect on pancreatic secretion. In the present study, intraperitoneal application of TMP increased secretion of pancreatic-bile juice (PBJ), but the protein content and pH value were not affected. It is known that PBJ consists of both bile and pancreatic juice, the volume of the basal secretion (or agonist induced) of pancreatic juice is normally very low, only about 9-18 μL in 15 minutes in rat^[17,18], as compared to that of




Figure 4 Pretreatment with IBMX decreased TMP-induced I_{SC} by 91 %. Values are $\bar{x} \pm s$, $^c P<0.001$.

the liver. Although TMP increased the secretion of PBJ by 26-83 μL in 15 minutes, it was difficult to assess the contribution to exocrine pancreatic secretion from our experiments *in vivo*. Therefore, CAPAN-1 cell line was used to further demonstrate the effect of TMP on the pancreatic secretion. Our data suggested that TMP could directly stimulate HCO_3^- secretion in human pancreatic duct cells.

According to the HCO_3^- secretory mode^[22], the intracellular HCO_3^- was accumulated from the tissue fluid via the basolateral membrane^[23-25] and mainly secreted by a $\text{Cl}^-/\text{HCO}_3^-$ exchanger^[26,27] and/or directly via cAMP/cGMP-dependent Cl^- channel (CFTR)^[13,26,28]. Recently, it was reported that CFTR could also secrete HCO_3^- as $\text{Cl}^-/\text{HCO}_3^-$ exchanger^[29,30]. The TMP-increased I_{SC} in CAPAN-1 could be blocked by Cl^- channel blockers, as well as phosphodiesterase inhibitors, which were known to increase cAMP and cGMP, and abolished by removal of extracellular HCO_3^- , suggesting that TMP can stimulate pancreatic HCO_3^- secretion via CFTR since it has been shown to be activated by both cAMP and cGMP. The TMP-induced increase in the volume of PBJ observed in the rats could be due to an increase in pancreatic HCO_3^- secretion, as well as bile secretion, leading to enhanced water secretion. However, the inability of TMP to increase the pH of PBJ appeared to contradict to its observed effect on the increase in HCO_3^- secretion. This could be explained by two possible reasons. One is that the mechanism of HCO_3^- secretion in human pancreatic duct cells was different from that in rats since the HCO_3^- concentration of pancreatic juice in rats was only 70 mmol/L while in human was 145 mmol/L ^[22]. The other is that the HCO_3^- secreted by the pancreas might be diluted by bile juice and thus having less prominent effect on pH. It is interesting to note that TMP could stimulate HCO_3^- secretion that could be inhibited by extracellular Cl^- as evidenced by the increase in the TMP-induced I_{SC} observed in the absence of extracellular Cl^- . However, the mechanism for the observed inhibition of HCO_3^- secretion by extracellular Cl^- remains to be elucidated.

In conclusion, the present *in vivo* and *in vitro* results suggest that TMP can promote the secretion of PBJ in rats and HCO_3^- secretion in human pancreatic duct cells, which may be beneficial to improving digestive function.

REFERENCES

- 1 **Zheng HZ**, Dong ZH, Yu J. Chuanxiong in: Zhongyao XiandaiYanjiu Yu Yingyong. 1st Ed. Beijing: Xueyuan Publisher 1997: 629-682
- 2 **Liu LS**, Chen MQ, Zeng GY, Zhou BF. A forty-year study on hypertension. *Zhongguo Yixue Kexue Yuan Xuebao* 2002; **24**: 401-408
- 3 **Cai Y**, Ren M, Yang R. Observation on curative effect of acute ischemic cerebrovascular disease treated with different dosage of ligustrazine. *Zhongguo Zhongxiyi Jiehe Zazhi* 2000; **20**: 747-749
- 4 **Liao F**. Herbs of activating blood circulation to remove blood stasis. *Clin Hemorheol Microcirc* 2000; **23**: 127-131
- 5 **Huang RJ**, Liao CX, Chen DZ. Effect of tetramethylpyrazine on endothelin, von Willebrand factor and thromboxane A2 during cardiopulmonary bypass in patients of congenital heart disease with pulmonary hypertension. *Zhongguo Zhongxiyi Jiehe Zazhi* 2003; **23**: 268-271
- 6 **Zou LY**, Hao XM, Zhang GQ, Zhang M, Guo JH, Liu TF. Effect of tetramethyl pyrazine on L-type calcium channel in rat ventricular myocytes. *Can J Physiol Pharmacol* 2001; **79**: 621-626
- 7 **Sheu JR**, Kan YC, Hung WC, Lin CH, Yen MH. The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase. *Life Sci* 2000; **67**: 937-947
- 8 **Lin CI**, Wu SL, Tao PL, Chen HM, Wei J. The role of cyclic AMP and phosphodiesterase activity in the mechanism of action of tetramethylpyrazine on human and dog cardiac and dog coronary arterial tissues. *J Pharm Pharmacol* 1993; **45**: 963-966
- 9 **Pei L**, Wang J. Protective effect of tetramethylpyrazine on red blood cells during autotransfusion. *Zhonghua Yixue Zazhi* 2002; **82**: 322-324
- 10 **Shih YH**, Wu SL, Chiou WF, Ku HH, Ko TL, Fu YS. Protective effects of tetramethylpyrazine on kainate-induced excitotoxicity in hippocampal culture. *Neuroreport* 2002; **13**: 515-519
- 11 **Zhang Z**, Wei T, Hou J, Li G, Yu S, Xin W. Tetramethylpyrazine scavenges superoxide anion and decreases nitric oxide production in human polymorphonuclear leukocytes. *Life Sci* 2003; **72**: 2465-2472
- 12 **Wu CC**, Liao MH, Chen SJ, Yen MH. Tetramethylpyradizine prevents inducible NO synthase expression and improves survival in rodent models of endotoxic shock. *Naunyn Schmiedebergs Arch Pharmacol* 1999; **360**: 435-444
- 13 **Kulaksiz H**, Schmid A, Honscheid M, Eissele R, Klempnauer J, Cetin Y. Guanylin in the human pancreas: a novel luminocrine regulatory pathway of electrolyte secretion via cGMP and CFTR in the ductal system. *Histochem Cell Biol* 2001; **115**: 131-145
- 14 **Gray M**, O' Reilly C, Winpenny J, Argent B. Anion interactions with CFTR and consequences for HCO₃⁻ transport in secretory epithelia. *J Korean Med Sci* 2000; **15**(Suppl): S12-15
- 15 **Shumaker H**, Amlal H, Frizzell R, Ulrich CD 2nd, Soleimani M. CFTR drives Na⁺-nHCO₃⁻ cotransport in pancreatic duct cells: a basis for defective HCO₃⁻ secretion in CF. *Am J Physiol* 1999; **276**(1Pt1): C16-25
- 16 **Lohi H**, Kujala M, Kerkela E, Saarialho-Kere U, Kestila M, Kere J. Mapping of five new putative anion transporter genes in human and characterization of SLC26A6, a candidate gene for pancreatic anion exchanger. *Genomics* 2000; **70**: 102-112
- 17 **Li JP**, Chang TM, Chey WY. Roles of 5-HT receptors in the release and action of secretin on pancreatic secretion in rats. *Am J Physiol Gastrointest Liver Physiol* 2001; **280**: G595-602
- 18 **Li JP**, Lee KY, Chang TM, Chey WY. MEK inhibits secretin release and pancreatic secretion: roles of secretin-releasing peptide and somatostatin. *Am J Physiol Gastrointest Liver Physiol* 2001; **280**: G890-896
- 19 **Li Y**, Wu XY, Zhu JX, Owyang C. Intestinal serotonin acts as paracrine substance to mediate pancreatic secretion stimulated by luminal factors. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G916-923
- 20 **Zhu JX**, Lo PS, Zhao WC, Tang N, Zhou Q, Rowlands DK, Gou YL, Chung YW, Chan HC. Bak Foong Pills stimulate anion secretion across normal and cystic fibrosis pancreatic duct epithelia. *Cell Biol Int* 2002; **26**: 1011-1018
- 21 **Cheng HS**, Wong WS, Chan KT, Wang XF, Wang ZD, Chan HC. Modulation of Ca²⁺-dependent anion secretion by protein kinase C in normal and cystic fibrosis pancreatic duct cells. *Biochim Biophys Acta* 1999; **1418**: 31-38
- 22 **Sohma Y**, Gray MA, Imai Y, Argent BE. HCO₃⁻ transport in a mathematical model of the pancreatic ductal epithelium. *J Membr Biol* 2000; **176**: 77-100
- 23 **Satoh H**, Moriyama N, Hara C, Yamada H, Horita S, Kunimi M, Tsukamoto K, Iso-O N, Inatomi J, Kawakami H, Kudo A, Endou H, Igarashi T, Goto A, Fujita T, Seki G. Localization of Na⁺-HCO₃⁻ cotransporter (NBC-1) variants in rat and human pancreas. *Am J Physiol Cell Physiol* 2003; **284**: C729-737
- 24 **Marino CR**, Jeanes V, Boron WF, Schmitt BM. Expression and distribution of the Na⁺-HCO₃⁻ cotransporter in human pancreas. *Am J Physiol* 1999; **277**(2 Pt1): G487-494
- 25 **Ishiguro H**, Naruse S, San Roman JI, Case M, Steward MC. Pancreatic Ductal Bicarbonate Secretion: Past, Present and future. *JOP* 2001; **2**(4 Suppl): 192-197
- 26 **Sohma Y**, Gray MA, Imai Y, Argent BE. 150 mM HCO₃⁻-how does the pancreas do it? Clues from computer modelling of the duct cell. *JOP* 2001; **2**(4 Suppl): 198-202
- 27 **Novak I**. Keeping up with bicarbonate. *J Physiol* 2000; **528** (Pt2): 235
- 28 **Ishiguro H**, Naruse S, Kitagawa M, Mabuchi T, Kondo T, Hayakawa T, Case RM, Steward MC. Chloride transport in microperfused interlobular ducts isolated from guinea-pig pancreas. *J Physiol* 2002; **539**(Pt1): 175-189
- 29 **Choi JY**, Muallem D, Kiselyov K, Lee MG, Thomas PJ, Muallem S. Aberrant CFTR-dependent HCO₃⁻ transport in mutations associated with cystic fibrosis. *Nature* 2001; **410**: 94-97
- 30 **Choi JY**, Lee MG, Ko S, Muallem S. Cl⁻-dependent HCO₃⁻ transport by cystic fibrosis transmembrane conductance regulator. *JOP* 2001; **2**(4 Suppl): 243-246

Edited by Wang XL